2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-155349
    AChE/BuChE-IN-4 1997158-25-4 99.66%
    AChE/BuChE-IN-4(compound 4a) is a multitarget-directed AChE/BuChE inhibitor againstAChEandBuChE, with the IC50 of 2.08 and 7.41 μM.
    AChE/BuChE-IN-4
  • HY-15691A
    PF-4455242 hydrochloride 1322001-35-3 99.01%
    PF-4455242 hydrochloride is an orally bioavailable, blood-brain barrier-permeable κ-opioid receptor (KOR) inhibitor. PF-4455242 hydrochloride blocks in vivo effects induced by KOR and MOR agonists, and elicits KOR-independent outward currents in ventral tegmental area neurons. PF-4455242 hydrochloride promotes energy expenditure and activates the hypothalamic mTOR pathway. PF-4455242 hydrochloride attenuates stress-induced behavioral effects and produces antidepressant-like effects. PF-4455242 hydrochloride can be used in studies related to pain, depression, addictive disorders, and obesity induced by estrogen withdrawal.
    PF-4455242 hydrochloride
  • HY-158821
    ISTH0036 2179222-27-4
    ISTH0036 is a phosphorothioate LNA-modified antisense oligonucleotide gapmer that selectively targets and downregulates TGF-β2 mRNA. ISTH0036 suppresses TGF-β2 expression, reduces choroidal neovascularization and vascular leakage, inhibits fibrosis, blocks epithelial-to-mesenchymal transition, and inhibits angiogenesis while promoting bleb survival. ISTH0036 exhibits long-lasting, dose-dependent ocular tissue distribution and target engagement in rabbit and non-human primate eyes. ISTH0036 can be used for the study of various ocular disorders, such as glaucoma and neovascular retinal diseases.
    ISTH0036
  • HY-159504
    Pregabalinum naproxencarbilum 1221072-91-8 98%
    Pregabalinum naproxencarbilum (Pregabalin naproxencarbil) is a gabamimetic (GABA) with analgesic effects. Pregabalinum naproxencarbilum is a nonopioid analgesic targeting both inflammatory and neuropathic pain signaling pathways.
    Pregabalinum naproxencarbilum
  • HY-159524
    Matsupexolum 1399442-97-7 98%
    Matsupexolum (Matsupexole) is a dopamine receptor agonist.
    Matsupexolum
  • HY-159527
    Glovadalenum 2576359-31-2 98%
    Glovadalenum (Glovadalen) is an orally active, selective, blood-brain barrier permeable positive allosteric modulator of dopamine D1 receptor. Glovadalenum selectively enhances the efficacy of dopamine in activating dopamine D1 receptor. Glovadalenum can be used for the research of Parkinson's disease.
    Glovadalenum
  • HY-163174
    II399 2928480-72-0 98%
    II399 is a potent, selective NNMT bisubstrate inhibitor containing an unconventional SAM mimic, with a Ki of 5.9 nM. II399 exhibits an explicit pattern of competitive inhibition for NAM. II399 occupies both the substrate and cofactor binding pockets. II399 has the potential for the research of cancers, metabolic, cardiovascular, and neurodegenerative diseases.
    II399
  • HY-168537
    LB-102 2227154-23-4 98.75%
    LB-102 is an orally active inhibitor of dopamine D2, D3, and 5-HT7 receptors, which can be used in research on schizophrenia and other psychiatric disorders.
    LB-102
  • HY-169964
    TSPO/Carbonic Anhydrase Modulator 1 98%
    TSPO/Carbonic Anhydrase Modulator 1 (Compound 3) is a dual modulator for mitochondrial translocator protein and Carbonic Anhydrase with a Ki of 1.340 μM for TSPO and a KA of 10.7 μM for CA VII. TSPO/Carbonic Anhydrase Modulator 1 promotes the production of neurosteroid, increases BDNF gene expression, exhibits neuroprotective efficacy.
    TSPO/Carbonic Anhydrase Modulator 1
  • HY-176266
    KIT-13 98%
    KIT-13 is an orally active plasmalogen derivative to inhibit neuroinflammation and mitochondrial DNA leakage associated with Mecp2 deficiency. KIT-13 significantly reduce neurological symptoms and improves the life span of the Rett Syndrome (RTT) model mice. KIT-13 can be used for the study of RTT and other neuroinflammation-related diseases.
    KIT-13
  • HY-177647
    Movronersen 2411937-33-0
    Movronersen is an antisense oligonucleotide targeted to α-synuclein.
    Movronersen
  • HY-181703
    4-PSQ 1415931-33-7
    4-PSQ is an orally active neuroprotective agent. 4-PSQ possesses both antioxidant and anti-inflammatory activities. 4-PSQ improves cognitive impairment and depressive- and anxiety-like emotional abnormalities in mice by regulating the activity of Na+, K+-ATPase, the NFκB signaling pathway, and the expression of p21. 4-PSQ can be used for the research of neurological diseases.
    4-PSQ
  • HY-183566
    MK-5661 2417328-24-4
    MK-5661 is an orally potent NaV1.8 voltage-gated sodium channel inhibitor with an EC50 of 4.3 nM. MK-5661 selectively inhibits peripheral nociceptive signaling mediators. MK-5661 reduces capsaicin-induced spontaneous nociceptive behaviors in humanized rats and attenuates capsaicin-induced skin flushing responses in rhesus monkeys. MK-5661 is applicable for pain-related research.
    MK-5661
  • HY-185316
    Brezosiran 3059403-91-4
    Brezosiran is a siRNA that inhibits huntingtin synthesis.
    Brezosiran
  • HY-34740R
    Ethylmalonic acid (Standard) 601-75-2
    Ethylmalonic acid (Standard) is the analytical standard of Ethylmalonic acid (HY-34740). This product is intended for research and analytical applications. Ethylmalonic acid is a short-chain organic dicarboxylic acid. Ethylmalonic acid synergistically induces mitochondrial permeability transition (MP) with Ca2+, inhibits Mi-CK, and disrupts mitochondrial energy metabolism. Ethylmalonic acid can be used in the research of SCADD, EE and other genetic metabolic diseases characterized by EMA accumulation.
    Ethylmalonic acid (Standard)
  • HY-B0551S
    Doxapram-d8 99.54%
    Doxapram-d8 is deuterated labeled Doxapram (HY-B0551). Doxapram is a respiratory stimulant. Doxapram increases breathing rate and depth by acting on the brain's respiratory centers and peripheral chemoreceptors. Doxapram inhibits TASK-1, TASK-3, TASK-1/TASK-3 heterodimeric channel function with EC50s of 410 nM, 37 μM, 9 μM, respectively. Doxapram inhibits the Ca²⁺-activated potassium current (IC50 ≈ 13 μM) and Ca²⁺-independent potassium current (IC50 ≈ 20 μM) in type I cells of the carotid body. Doxapram significantly prolongs the effective refractory period of the atrium and has an anti-arrhythmic effect. Doxapram can be used for the study of respiratory depression such as post-anesthesia respiratory depression, chronic obstructive pulmonary disease and apnea of prematurity.
    Doxapram-d8
  • HY-B1331R
    Cyromazine (Standard) 66215-27-8 99.71%
    Cyromazine (Standard) is the analytical standard of Cyromazine. This product is intended for research and analytical applications. Cyromazine (CGA-72662) is a triazine insect growth regulator used as an insecticide and an acaricide. It is a cyclopropyl derivative of melamine. Cyromazine works by affecting the nervous system of the immature larval stages of certain insects. Cyromazine reduced the number of germ cells by interfering with the Ecdysone (HY-N0179) signaling pathway. Cyromazine induces renal toxicity attenuated and restored by green tea extract in rats.
    Cyromazine (Standard)
  • HY-B1470S
    Azaperone-d4 1173021-72-1
    Azaperone-d4 (R-1929-d4) is the deuterium labeled Azaperone (HY-B1470). Azaperone is an antagonist of dopamine D2 receptor (Dopamine D2 Receptor) and α-adrenergic receptor (AR). Azaperone reduces vasomotor tone, mean arterial pressure, hematocrit, hemoglobin concentration, and etorphine-induced duration; induces transient tachycardia followed by bradycardia, splenic uptake of red blood cells, and sedation; alters animal behaviors; and produces sedation with distinct onset and duration in foals. Azaperone is used for sedation and tranquilization in various animals to reduce stress and aggressive behaviors, and serves as a preanesthetic agent.
    Azaperone-d4
  • HY-B2082R
    Fursultiamine (Standard) 804-30-8 98%
    Fursultiamine (Standard) is the analytical standard of Fursultiamine. This product is intended for research and analytical applications. Fursultiamine is a vitamin B1 derivative, has anti-nociceptive and antineoplastic activity. Fursultiamine can be used for vitamin B1 deficiency, osteoarthritis (OA) and cancer research.
    Fursultiamine (Standard)
  • HY-N0698R
    Crocin II (Standard) 55750-84-0
    Crocin II (Standard) is the analytical standard of Crocin II. This product is intended for research and analytical applications. Crocin II is an inhibitor targeting α-synuclein aggregation, with a IC50 of 0.541 μM and a EC50 of 3.63 μM. Crocin II inhibits α-synuclein aggregation and dissociates pre-formed α-synuclein fibrils. Crocin II possesses antioxidant, anticancer and antidepressant activities. Crocin II is applicable to research related to neurological disorders such as Parkinson's disease, dementia with Lewy bodies and multiple system atrophy, as well as cancers.
    Crocin II (Standard)
Cat. No. Product Name / Synonyms Application Reactivity